<!DOCTYPE html>
<html lang="en-us">
  <head>
	<meta name="generator" content="Hugo 0.85.0" />
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    <title>fallingstar-Daily-rss | Fallingstar Daily R</title>
    <link rel="stylesheet" href="/css/style.css" />
    <link rel="stylesheet" href="/css/fonts.css" />
    <link href="//cdn.bootcss.com/highlight.js/9.12.0/styles/github.min.css" rel="stylesheet">

  </head>

  <body>
    <nav class="header">
      <div class="banner">
<a href="/" class="text">
&Ffr;&Afr;&Lfr;&Lfr;&Ifr;&Nfr;&Gfr;&Sfr;&Tfr;&Afr;&Rfr; &Dfr;&Afr;&Ifr;&Lfr;&Yfr; &Rfr;
</a>
</div>

      <div class="head-meta">
      
        <span>fallingstar-Daily-rss</span>
        <span>2024-11-30</span>
      
      </div>
    </nav>


<div class="container">
<main class="list">

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39397690">Clostridium sporogenes-derived metabolites protect mice against colonic inflammation.</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-30</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39397690/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted -->Felix F Krause<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->Â <!-- raw HTML omitted --><!-- raw HTML omitted --> 1 <!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39609952/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241129173059&amp;v=2.18.0.post9&#43;e462414">Multisocietal Consensus on the Use of Cytoreductive Surgery and HIPEC for the Treatment of Diffuse Malignant Peritoneal Mesothelioma: A GRADE Approach for Evidence Evaluation and Recommendation</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39609952-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241129173059-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The Peritoneal Surface Oncology Group International (PSOGI) previously issued a recommendation endorsing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treating diffuse malignant peritoneal mesothelioma (DMPM). However, broader acceptance of this approach, particularly within some segments of medical oncology, remains limited. To address this, PSOGI initiated a multisociety consensus effort, involving multidisciplinary International Societies, to &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39609952/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241130171400&amp;v=2.18.0.post9&#43;e462414">Multisocietal Consensus on the Use of Cytoreductive Surgery and HIPEC for the Treatment of Diffuse Malignant Peritoneal Mesothelioma: A GRADE Approach for Evidence Evaluation and Recommendation</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39609952-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241130171400-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The Peritoneal Surface Oncology Group International (PSOGI) previously issued a recommendation endorsing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treating diffuse malignant peritoneal mesothelioma (DMPM). However, broader acceptance of this approach, particularly within some segments of medical oncology, remains limited. To address this, PSOGI initiated a multisociety consensus effort, involving multidisciplinary International Societies, to &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39610217/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241129173059&amp;v=2.18.0.post9&#43;e462414">&#34;There Is No Peace&#34;, &#34;We Are Just Persevering&#34;: Triggers, Manifestations, and Consequences of Intimate Partner Violence Against Men in Kenya</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39610217-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241129173059-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Intimate partner violence (IPV) within heterosexual relationships affects both men and women, yet an in-depth description of IPV against men in developing countries is still limited. This study explored community perceptions of male IPV victimization in an informal settlement in Nairobi, Kenya. We conducted 12 focus group discussions (FGDs) with 118 ever-married participants (59 men and 59 women), divided into 6 FGDs for each gender. We performed thematic analysis using NVivo software. &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39610217/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241130171400&amp;v=2.18.0.post9&#43;e462414">&#34;There Is No Peace&#34;, &#34;We Are Just Persevering&#34;: Triggers, Manifestations, and Consequences of Intimate Partner Violence Against Men in Kenya</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39610217-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241130171400-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Intimate partner violence (IPV) within heterosexual relationships affects both men and women, yet an in-depth description of IPV against men in developing countries is still limited. This study explored community perceptions of male IPV victimization in an informal settlement in Nairobi, Kenya. We conducted 12 focus group discussions (FGDs) with 118 ever-married participants (59 men and 59 women), divided into 6 FGDs for each gender. We performed thematic analysis using NVivo software. &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39610364/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241129173059&amp;v=2.18.0.post9&#43;e462414">A Retrospective Single-Center Study in 20 Patients With Midline Nasal Masses: Which Site Has the Highest Risk of Recurrence?</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39610364-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241129173059-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: All recurrences had a superficial extension and were easily excised. Intraosseous NDSC have the highest risk of recurrence, but conversely, they also occur most &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39610364/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241130171400&amp;v=2.18.0.post9&#43;e462414">A Retrospective Single-Center Study in 20 Patients With Midline Nasal Masses: Which Site Has the Highest Risk of Recurrence?</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39610364-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241130171400-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: All recurrences had a superficial extension and were easily excised. Intraosseous NDSC have the highest risk of recurrence, but conversely, they also occur most &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39611442/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241129173059&amp;v=2.18.0.post9&#43;e462414">Gadolinium leakage into ocular structures as a marker in stroke: A retrospective analysis of the WAKE-UP trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39611442-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241129173059-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    INTRODUCTION: Blood-brain barrier disruption in acute ischemic stroke is a well described phenomenon associated with hemorrhagic complications. The hyperintense acute reperfusion marker (HARM) represents gadolinium leakage in the cerebrospinal fluid. Gadolinium leakage into ocular structures (GLOS) might represent a dysfunction of the blood-ocular barrier. We aimed to investigate the presence of GLOS in the WAKE-UP trial and its association with HARM, hemorrhagic transformation (HT) &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39611442/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241130171400&amp;v=2.18.0.post9&#43;e462414">Gadolinium leakage into ocular structures as a marker in stroke: A retrospective analysis of the WAKE-UP trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39611442-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241130171400-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    INTRODUCTION: Blood-brain barrier disruption in acute ischemic stroke is a well described phenomenon associated with hemorrhagic complications. The hyperintense acute reperfusion marker (HARM) represents gadolinium leakage in the cerebrospinal fluid. Gadolinium leakage into ocular structures (GLOS) might represent a dysfunction of the blood-ocular barrier. We aimed to investigate the presence of GLOS in the WAKE-UP trial and its association with HARM, hemorrhagic transformation (HT) &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39611618/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241129173059&amp;v=2.18.0.post9&#43;e462414">&lt;sup&gt;13&lt;/sup&gt;C Stable Isotope Tracing Reveals Distinct Fatty Acid Oxidation Pathways in Proliferative vs. Oxidative Cells</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39611618-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241129173059-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The TCA cycle serves as a central hub to balance catabolic and anabolic needs of the cell, where carbon moieties can either contribute to oxidative metabolism or support biosynthetic reactions. This differential TCA cycle engagement for glucose-derived carbon has been extensively studied in cultured cells, but the fate of fatty acid (FA)-derived carbons is poorly understood. To fill the knowledge gap, we have developed a strategy to culture cells with long-chain FAs without altering &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39611618/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241130171400&amp;v=2.18.0.post9&#43;e462414">&lt;sup&gt;13&lt;/sup&gt;C Stable Isotope Tracing Reveals Distinct Fatty Acid Oxidation Pathways in Proliferative vs. Oxidative Cells</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39611618-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241130171400-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The TCA cycle serves as a central hub to balance catabolic and anabolic needs of the cell, where carbon moieties can either contribute to oxidative metabolism or support biosynthetic reactions. This differential TCA cycle engagement for glucose-derived carbon has been extensively studied in cultured cells, but the fate of fatty acid (FA)-derived carbons is poorly understood. To fill the knowledge gap, we have developed a strategy to culture cells with long-chain FAs without altering &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39612012/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241129173059&amp;v=2.18.0.post9&#43;e462414">Quality of care of oncological patients with home parenteral nutrition</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39612012-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241129173059-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: With thorough preparation for home parenteral nutrition, the transition from hospital to home care environment works well. QoL is largely maintained through HPN, and cancer patients perceive this situation as not or minimally burdensome alongside their underlying disease, although many patients found the limited mobility to be a &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39612012/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241130171400&amp;v=2.18.0.post9&#43;e462414">Quality of care of oncological patients with home parenteral nutrition</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39612012-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241130171400-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: With thorough preparation for home parenteral nutrition, the transition from hospital to home care environment works well. QoL is largely maintained through HPN, and cancer patients perceive this situation as not or minimally burdensome alongside their underlying disease, although many patients found the limited mobility to be a &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39612561/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241130171400&amp;v=2.18.0.post9&#43;e462414">Expression of the mucin-like glycoprotein CD24 and its ligand siglec-10 in placentas with acute and post SARS-CoV-2 infection</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39612561-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241130171400-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CD24 is a mucin-like glycoprotein expressed on trophoblast cells and endothelial tissue of first and third trimester placentas. As an immune suppressor, CD24 may contribute to maternal immune tolerance to the growing fetus. CD24 is known to interact with the sialic acid-binding immunoglobulin-type lectins (Siglecs), specifically siglec-10. The aim of this study was to investigate the expression of both, CD24 and siglec-10 on placental tissue slides from acute covid patients, patients &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39612757/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241130171400&amp;v=2.18.0.post9&#43;e462414">Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39612757-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241130171400-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Clinical response evaluated in the first months of therapy is a strong predictor of long-term survival, even in patients with poor prognostic &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39612915/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241130171400&amp;v=2.18.0.post9&#43;e462414">Interleukin-2-secreting T helper cells promote extra-follicular B cell maturation via intrinsic regulation of a B cell mTOR-AKT-Blimp-1 axis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39612915-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241130171400-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    During antigen-driven responses, B cells can differentiate at extra-follicular (EF) sites or initiate germinal centers (GCs) in processes that involve interactions with T cells. Here, we examined the roles of interleukin (IL)-2 secreted by T helper (Th) cells during cognate interactions with activated B cells. IL-2 boosted the expansion of EF plasma cells and the secretion of low-mutated immunoglobulin G (IgG). Conversely, genetically disrupting IL-2 expression by CD4^(+) T cells, or &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39613289/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241130171400&amp;v=2.18.0.post9&#43;e462414">Novel techniques to quantitatively assess age-dependent alterations in biophysical properties of HSPCs and bone marrow niche</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39613289-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241130171400-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The present knowledge on hematopoietic stem and progenitor cell (HSPC) biology and aging is based largely on studies in mouse models. While mouse models are invaluable, they are not without limitations for defining how physical properties of HSPCs and their niche change with age. The bone marrow (BM) niche is a complex, interactive environment with multiple cell types. The structure and organization of the BM niche, especially the extracellular matrix (ECM), change with age. Provided with &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39613322/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241130171400&amp;v=2.18.0.post9&#43;e462414">Endovascular therapy versus medical management in isolated anterior cerebral artery acute ischemic stroke: a multinational multicenter propensity score-weighted study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39613322-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241130171400-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: EVT showed high procedural success but did not significantly improve functional outcomes or mortality compared with BMT in patients with ACAo. Further randomized trials are needed to clarify EVT&rsquo;s role in &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39613747/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241130171400&amp;v=2.18.0.post9&#43;e462414">Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39613747-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241130171400-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The long-term consequences of cancer and its therapy on the patients' immune system years after cancer-free survival remain poorly understood. Here, we present an in-depth characterization of the bone marrow immune ecosystem of multiple myeloma long-term survivors, from initial diagnosis up to 17 years following a single therapy line and cancer-free survival. Using comparative single-cell analyses combined with molecular, genomic, and functional approaches, we demonstrate that multiple &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39613843/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241130171400&amp;v=2.18.0.post9&#43;e462414">Tumor budding and lymphovascular invasion as prognostic factors in p16-positive oropharyngeal squamous cell carcinomas</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39613843-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241130171400-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In addition to LVI, we could identify TB as an independent prognostic factor in p16-positive OPSCC in this multicenter study cohort. Thus, evaluating TB along with LVI in a combined scheme for prognostication might help to establish a more personalized treatment regimen for patients with p16-positive &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39614005/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241130171400&amp;v=2.18.0.post9&#43;e462414">ASO Visual Abstract: Definition and Predictors of Early Recurrence in Neoadjuvantly Treated Esophageal and Gastroesophageal Adenocarcinoma-A Dual-Center Retrospective Cohort Study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39614005-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241130171400-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39614103/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241130171400&amp;v=2.18.0.post9&#43;e462414">Sociodemographic and clinical factors associated with low muscle mass and composition in people treated with (chemo)radiotherapy for lung cancer</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39614103-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241130171400-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In patients with lung cancer, there is some evidence anthropometric measures of muscle mass are suggestive of low muscle mass pre-radiotherapy, while low energy intake pre-treatment may indicate low muscle radiodensity after treatment. However, these findings are limited by the small sample size and further prospective studies with larger samples are &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/P2wdH9aiV">å¨å å·æå¤§çä¸ä¸ªå¥½å¤æ¯å°å¤å¨å¤·å¾å®¹æï¼è¿å»ä¸å¹´ææ©èé½æ¯å¨å¤å¨å¤·åº¦è¿çï¼åå«å»äºKauaiï¼Mauiï¼Big Islandï¼è¿æ¬¡æ¥å°äºå¤å¨å¤·æåä¸ä¸ªä¸»è¦çå²ï¼OahuãWaiki...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-p2wdh9aiv/">
    
    
    
    
    
      
    
    å¨å å·æå¤§çä¸ä¸ªå¥½å¤æ¯å°å¤å¨å¤·å¾å®¹æï¼è¿å»ä¸å¹´ææ©èé½æ¯å¨å¤å¨å¤·åº¦è¿çï¼åå«å»äºKauaiï¼Mauiï¼Big Islandï¼è¿æ¬¡æ¥å°äºå¤å¨å¤·æåä¸ä¸ªä¸»è¦çå²ï¼OahuãWaikiki - Honoluluçæ¯ä¸ªå¤§åå¸ï¼åMiami BeachåVegasçç»åï¼ä¸ä¸ªä¸ªååºè¿èµ·æ¥ã <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ç¾å½Â·Hawaii wakiki bayUSA<!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax1.sinaimg.cn/large/4a994b1dgy1hw2vbn5wu0j24eo3b0kjp.jpg%22">https://tvax1.sinaimg.cn/large/4a994b1dgy1hw2vbn5wu0j24eo3b0kjp.jpg&quot;</a> referrerpolicy=&ldquo;no-refer &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/P2wqFrGuZ">è¿æå¤å°äººåæä¸æ ·åæä¸ä¸æé³çð¿</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-p2wqfrguz/">
    
    
    
    
    
      
    
    è¿æå¤å°äººåæä¸æ ·åæä¸ä¸æé³çð¿  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/P2wtRuRuU">æ´å»·æ¡&#43;ä¸åè¾½=ç³çè° [å¾ç]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-p2wtruruu/">
    
    
    
    
    
      
    
    æ´å»·æ¡+ä¸åè¾½=ç³çè° <!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/P2wVaBEEA">æ¥äºä¸å¯¹å¼æ¥å¿ï¼åç°ä¸ä¸ªç¹å«æè¶£çäºæãå¨äºä¸åå¼å§ä¸æ£çäººææ¾æ¯å¨ä¸~å¨åå¤äºèµ·æ¥ï¼æç¶æåä¸å¤©é½è¦æ¸é±¼[æ]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-p2wvabeea/">
    
    
    
    
    
      
    
    æ¥äºä¸å¯¹å¼æ¥å¿ï¼åç°ä¸ä¸ªç¹å«æè¶£çäºæã<!-- raw HTML omitted -->å¨äºä¸åå¼å§ä¸æ£çäººææ¾æ¯å¨ä¸~å¨åå¤äºèµ·æ¥ï¼æç¶æåä¸å¤©é½è¦æ¸é±¼<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/P2A0UiKf5">æè¡¥è¯ä¸ç­ð­</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-p2a0uikf5/">
    
    
    
    
    
      
    
    æè¡¥è¯ä¸ç­ð­  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/P2A1adWT5">è½¬åå¾®å - è½¬å @é¡¶ç­TENä½¿:&amp;ensp;ä¹ä¿å²ç»ªé via.nogizaka_goods [å¾ç][å¾ç][å¾ç]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-p2a1adwt5/">
    
    
    
    
    
      
    
    è½¬åå¾®å<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å <!-- raw HTML omitted -->@é¡¶ç­TENä½¿<!-- raw HTML omitted -->:â<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹ä¿å²ç»ªé<!-- raw HTML omitted --><!-- raw HTML omitted --> via.nogizaka_goods &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax4.sinaimg.cn/large/006z6nxLgy1hw3a494ecej30m80m8jsd.jpg%22">https://tvax4.sinaimg.cn/large/006z6nxLgy1hw3a494ecej30m80m8jsd.jpg&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/P2A3WlkIj">å·²ç»ä¸¤ä¸ªæäºï¼æ³å¿µå®¶äºº</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-p2a3wlkij/">
    
    
    
    
    
      
    
    å·²ç»ä¸¤ä¸ªæäºï¼æ³å¿µå®¶äºº  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/P2A41mJ2L">åäººä¸ºä»ä¹ä¼åå¾å°å¿ç¿¼ç¿¼</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-p2a41mj2l/">
    
    
    
    
    
      
    
    åäººä¸ºä»ä¹ä¼åå¾å°å¿ç¿¼ç¿¼  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/P2DD4bqOb">æåºä¹å¨å¹´ä¸æçliveè¿è¡æ¯å¯¹//@åºè¯å·¨å¤R:ä¸è®¤è¯ åçç//@å°å·å½©æ¬äºº:ä½ è°//@å«éªæå¿çmaxåå¡:ç»äºï¼çççå§ - è½¬å @é¢é¢åªæ³ç»é¹é¹å½ç:&amp;ensp;æ¨ãã®å­ ...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-p2dd4bqob/">
    
    
    
    
    
      
    
    æåºä¹å¨å¹´ä¸æçliveè¿è¡æ¯å¯¹//<!-- raw HTML omitted -->@åºè¯å·¨å¤R<!-- raw HTML omitted -->:ä¸è®¤è¯ åçç//<!-- raw HTML omitted -->@å°å·å½©æ¬äºº<!-- raw HTML omitted -->:ä½ è°//<!-- raw HTML omitted -->@å«éªæå¿çmaxåå¡<!-- raw HTML omitted -->:ç»äºï¼çççå§<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å <!-- raw HTML omitted -->@é¢é¢åªæ³ç»é¹é¹å½ç<!-- raw HTML omitted -->:âæ¨ãã®å­ æéç±/æè¤é£é¸liveçæ®µ<!-- raw HTML omitted -->æè§åæ¥äº<!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/p/index?extparam=%E6%96%8B%E8%97%A4%E9%A3%9E%E9%B8%9F&amp;amp;containerid=100808eb40d96f33648b7f43b6529f2">https://m.weibo.cn/p/index?extparam=%E6%96%8B%E8%97%A4%E9%A3%9E%E9%B8%9F&amp;amp;containerid=100808eb40d96f33648b7f43b6529f2</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/P2DDVC46T">åæ¯ä¸ºäºæð©ç¶åæå¿èä¹±çä¸ä¸ªæ©ä¸</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-p2ddvc46t/">
    
    
    
    
    
      
    
    åæ¯ä¸ºäºæð©ç¶åæå¿èä¹±çä¸ä¸ªæ©ä¸  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/P2x7DthA5">å¥½æ³åç¸é¸¡</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-p2x7dtha5/">
    
    
    
    
    
      
    
    å¥½æ³åç¸é¸¡  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/P2yv8pSdG">æå½å¥½å°ââæ´è¡£æºç©å¹²åäºæµ´å·¾æ²¡å¹²éæä¹ååð­</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-p2yv8psdg/">
    
    
    
    
    
      
    
    æå½å¥½å°ââæ´è¡£æºç©å¹²åäºæµ´å·¾æ²¡å¹²éæä¹ååð­  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/P2yxL0CFg">æ¨çæ¯è¿ç§äººå¥½å¤ï¼æå½yunaå¥½å¥½ç//@Nyarth09:å°±æ¯æè¿ç§å»é¼é¥­æä¼æå¾å¶åæ²¡æäººå³ - è½¬å @ç´è¯åå±æ°2:&amp;ensp;(ä¸­å­)æè¢«å ä¸è´é¢å½¢è±¡ï¼ç­äºå½©èãæ´ç°æè...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-p2yxl0cfg/">
    
    
    
    
    
      
    
    æ¨çæ¯è¿ç§äººå¥½å¤ï¼æå½yunaå¥½å¥½ç//<!-- raw HTML omitted -->@Nyarth09<!-- raw HTML omitted -->:å°±æ¯æè¿ç§å»é¼é¥­æä¼æå¾å¶åæ²¡æäººå³<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å <!-- raw HTML omitted -->@ç´è¯åå±æ°2<!-- raw HTML omitted -->:â(ä¸­å­)æè¢«å ä¸è´é¢å½¢è±¡ï¼ç­äºå½©èãæ´ç°æèç´æ­æ¶è¯´è¯å°å¿ç¿¼ç¿¼ç»æä»è¢«ç½åéª<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/P2BfNpKsQ">æ£ææé¹° è¿å¥½æå¤©å¯ä»¥æ¿è¡¥ç­¾å¡ [å¾ç]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-p2bfnpksq/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æ£ææé¹°<!-- raw HTML omitted --><!-- raw HTML omitted --> è¿å¥½æå¤©å¯ä»¥æ¿è¡¥ç­¾å¡ <!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/P2xSLAvc8">ãéæ¥ãå°äº11æ30æ¥å12æ1æ¥è¿è¡çå¹¿å²éå¶æ¯è¥é²¤æï¼åå®åå æ¯èµçä¸éç±å²ç¾å ä¸ºåå å´æ¸æºæ¯å³èµï¼æç»å³å®æåå¿ä¿é¡¶æ¿ä¸éç±å²ç¾åèµã</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-p2xslavc8/">
    
    
    
    
    
      
    
    ãéæ¥ãå°äº11æ30æ¥å12æ1æ¥è¿è¡çå¹¿å²éå¶æ¯è¥é²¤æï¼åå®åå æ¯èµçä¸éç±å²ç¾å ä¸ºåå å´æ¸æºæ¯å³èµï¼æç»å³å®æåå¿ä¿é¡¶æ¿ä¸éç±å²ç¾åèµã  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/P2zsnnSw5">è¥é²¤æç¬¬ä¸è½®å¯¹éµè¤æ³½éèæä¹é½æ²¡æ³å°ç¬¬ä¸è½®å°±éå°èªå·±å¥½å§å¦¹å¥½å§å¦¹ä¼°è®¡ä¹æ²¡æ³å°ä¼é¡¶æ¿ä¸éç±å²ç¾åèµï¼å ä¸ºé¢éå³èµæåå¿ä¿è¾ç»äºä¸éç±å²ç¾ï¼æä»¥éè¡¥äºï¼å¾...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-11-29</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-p2zsnnsw5/">
    
    
    
    
    
      
    
    è¥é²¤æç¬¬ä¸è½®å¯¹éµ<!-- raw HTML omitted --><!-- raw HTML omitted -->è¤æ³½éèæä¹é½æ²¡æ³å°ç¬¬ä¸è½®å°±éå°èªå·±å¥½å§å¦¹<!-- raw HTML omitted -->å¥½å§å¦¹ä¼°è®¡ä¹æ²¡æ³å°ä¼é¡¶æ¿ä¸éç±å²ç¾åèµ<!-- raw HTML omitted -->ï¼å ä¸ºé¢éå³èµæåå¿ä¿è¾ç»äºä¸éç±å²ç¾ï¼æä»¥éè¡¥äºï¼<!-- raw HTML omitted --><!-- raw HTML omitted -->å¾çï¼æ£éweb <!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

</main>
</div>

<script async src="//yihui.name/js/center-img.js"></script>

<footer>

<div class="footer">
  <ul class="menu">
    
    <li><a href="/"><span data-hover="Home">Home</span></a></li>
    
    <li><a href="/about/"><span data-hover="About">About</span></a></li>
    
    <li><a href="/archives/"><span data-hover="Archive">Archive</span></a></li>
    
    <li><a href="/contributor/"><span data-hover="Contributor">Contributor</span></a></li>
    
    <li><a href="/index.xml"><span data-hover="Subscribe">Subscribe</span></a></li>
    
  </ul>
  
  <div class="copyright">Â© <a href="https://rainoffallingstar.github.io">Fallingstar</a> 2023 | <a href="https://github.com/rainoffallingstar">Github</a></div>
  
</div>
</footer>







</body>
</html>

